PGM2L1

Across TCGA pan-cancer cohorts, PGM2L1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PGM2L1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PGM2L1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PGM2L1 is over-expressed in tumor.

CCRCC, PDAC, and LUAD are the cancer types where PGM2L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGM2L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.879	<.001	12	view →
PDAC	Female	II,III,IV	+0.791	<.001	10	view →
LUAD	Male	III,IV	+0.973	<.001	9	view →
HNSC	All	IV	+0.617	<.001	8	view →
LSCC	Female	All	+0.556	<.001	6	view →
COAD	Female	III,IV	+0.261	.006	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PGM2L1–CCRCC

Open the CCRCC breakdown →